Hosted on MSN29d
Callio raises $187m for proof-of-concept for dual-payload ADC
Callio Therapeutics has raised $187m in a Series A financing round to achieve clinical proof-of-concept for its human epidermal growth factor receptor 2-targeted dual-payload antibody-drug ...
Business Insider20d
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs ...
Nasdaq20d
Sutro Biopharma Prioritizes Next-Generation ADC Programs and Announces Leadership Transition
Sutro Biopharma, Inc. announced a strategic shift focusing on its next-generation exatecan and dual-payload antibody drug conjugate (ADC) programs, deprioritizing the development of luveltamab ...
FierceBiotech1mon
Frazier arms Callio with $187M series A to fly Hummingbird's HER2 dual payload ADC to clinic
Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload antibody-drug conjugate that’s ready for the clinic. The ADC ...
Seeking Alpha20d
Sutro Biopharma rises after market hours on portfolio review, restructuring
Sutro Biopharma (NASDAQ:STRO) said on Thursday that, under its portfolio review, the company has decided to advance its dual-payload ADC programs, while deprioritizing development of luveltamab ...